Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 7, 2020• Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 • If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s diseaseCAMBRIDGE, Mass. and TOKYO, August 7, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Jul 24, 2020- One oral presentation and eight posters, highlighting Eisai's investigational novel therapies being studied to treat Alzheimer's disease (AD) and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and information from the company's robust AD pipeline, including BAN2401 and...
-
Jul 13, 2020
The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, United...
-
Jul 8, 2020If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease
CAMBRIDGE, Mass. and TOKYO, July 8, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics...
-
Jun 1, 2020
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO® (lemborexant) CIV for the treatment of adults with insomnia, characterized by...